Skip to content

Trial Summary

This study aims to aims to test whether treatment with simvastatin during docetaxel chemotherapy for metastatic castration-resistant prostate cancer can reverse a poor prognostic plasma lipid signature.

Acronym:

Statins-Lipodomics

ACTRN/NCT /ethics:

ACTRN12617000965303

Scientific title:

A multi-centre, open-label trial of simvastatin in addition to docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

Sponsor / Cooperative group:

Chris O’Brien Lifehouse

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhaseAll phases
Age Range18 years and older
SexMale
Tumour Stream Prostate
Cancer StageMetastatic or Widespread
Anticipated Start Date2018-05-01
Anticipated End Date2019-09-30

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Francis Parnis
Recruitment StatusRecruiting